What is NDC 70069-838?

70069-838 is the product NDC for Eltrombopag olamine, Eltrombopag olamine 25 mg/1 tablet, film coated, listed with the FDA by Somerset Therapeutics, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Somerset Therapeutics, LLC, NDC labeler code 70069. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Eltrombopag olamine?

19 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Eltrombopag olamine NDC 70069-838 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)70069-838Labeler and product segments. Claims need a package NDC.

Product NDC at billing width70069-0838Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
70069-838-01	7006908380170069083801	30 TABLET, FILM COATED in 1 BOTTLE (70069-838-01)Marketed from Jan 14, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Eltrombopag olamine
Generic name (nonproprietary): eltrombopag olamine
Active ingredients: Eltrombopag olamine — 25 mg/1
Dosage form: Tablet, Film coated
Route: Oral
Labeler: Somerset Therapeutics, LLCNDC labeler code 70069
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 219638
Marketing start: Jan 14, 2026
Listing expires: Dec 31, 2027
Other FDA classes: Breast Cancer Resistance Protein Inhibitors (Mechanism)Increased Megakaryocyte Maturation (Physiologic effect)Increased Platelet Production (Physiologic effect)Organic Anion Transporting Polypeptide 1B1 Inhibitors (Mechanism)Thrombopoietin Receptor Agonists (Mechanism)UGT1A1 Inhibitors (Mechanism)UGT1A3 Inhibitors (Mechanism)UGT1A4 Inhibitors (Mechanism)UGT1A6 Inhibitors (Mechanism)UGT1A9 Inhibitors (Mechanism)UGT2B15 Inhibitors (Mechanism)UGT2B7 Inhibitors (Mechanism)
Identifiers: Product ID 70069-838_ec6939e2-4f64-4edd-848c-83e73ffac433SPL ID ec6939e2-4f64-4edd-848c-83e73ffac433SPL set ID 604f663c-4933-402a-8105-5921713cf3c8RxCUI 825421, 825427, 884617, 1245001UNII 4U07F515LGUPC 0370069838013, 0370069840016, 0370069839010, 0370069837016
Pharmacologic class: Thrombopoietin Receptor Agonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N470069083801 followed by a unit qualifier and the quantity

Package 70069-0838-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 13, 2026. This label includes a boxed warning.

Indications (excerpt from the label)

Eltrombopag tablets are thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. (1.1) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thromb…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 70069-838

What is NDC 70069-838?: 70069-838 is the product NDC for Eltrombopag olamine, Eltrombopag olamine 25 mg/1 tablet, film coated, listed with the FDA by Somerset Therapeutics, LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Eltrombopag olamine.
What is the active ingredient?: Eltrombopag olamine.
Who is the labeler?: Somerset Therapeutics, LLC, NDC labeler code 70069. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Eltrombopag olamine?: 19 other product NDCs are listed under this name. See all Eltrombopag olamine NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Eltrombopag olamine NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Eltrombopag olamine	Eltrombopag olamine 12.5 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-032	87564-0032-30
Eltrombopag olamine	Eltrombopag olamine 25 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-033	87564-0033-30
Eltrombopag olamine	Eltrombopag olamine 50 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-034	87564-0034-30
Eltrombopag olamine	Eltrombopag olamine 75 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-035	87564-0035-30
Eltrombopag Olamineeltrombopag	Eltrombopag olamine 12.5 mg/1	Tablet, Film coatedOral	AvKARE	42291-932	42291-0932-30
Eltrombopag Olamineeltrombopag	Eltrombopag olamine 25 mg/1	Tablet, Film coatedOral	AvKARE	42291-933	42291-0933-30
Eltrombopag Olamineeltrombopag	Eltrombopag olamine 50 mg/1	Tablet, Film coatedOral	AvKARE	42291-934	42291-0934-30
Eltrombopag Olamineeltrombopag	Eltrombopag olamine 75 mg/1	Tablet, Film coatedOral	AvKARE	42291-935	42291-0935-30
Eltrombopag Olamineeltrombopag	Eltrombopag olamine 75 mg/1	Tablet, Film coatedOral	Amneal Pharmaceuticals NY LLC	60219-1414	60219-1414-03
Eltrombopag Olamineeltrombopag	Eltrombopag olamine 50 mg/1	Tablet, Film coatedOral	Amneal Pharmaceuticals NY LLC	60219-1415	60219-1415-03

All 20 Eltrombopag olamine NDCs

Other NDCs under ANDA 219638

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 219638
Product	Strength	Form · route	Labeler	Product NDC
Eltrombopag olamine	Eltrombopag olamine 12.5 mg/1	Tablet, Film coatedOral	Somerset Therapeutics, LLC	70069-837
Eltrombopag olamine	Eltrombopag olamine 50 mg/1	Tablet, Film coatedOral	Somerset Therapeutics, LLC	70069-839
Eltrombopag olamine	Eltrombopag olamine 75 mg/1	Tablet, Film coatedOral	Somerset Therapeutics, LLC	70069-840
Eltrombopag olamine	Eltrombopag olamine 12.5 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-032
Eltrombopag olamine	Eltrombopag olamine 25 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-033
Eltrombopag olamine	Eltrombopag olamine 50 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-034
Eltrombopag olamine	Eltrombopag olamine 75 mg/1	Tablet, Film coatedOral	Amerisyn, LLC	87564-035